Clinical-Stage AI Platform  
Advancing NextGen Immunomodulators  for Rare and Inflammatory Diseases

A common pathway across many devastating diseases

Multiple-mechanism-of-action protein targets enable us to develop novel therapies for inflammatory diseases.
Our focus is on those devastating diseases which currently have no effective treatment, cause suffering to millions of patients and their families and cost society billions of dollars.

Pulmonary
ARDS
Cystic Fibrosis
Pneumonia
Bronchiolitis Obliterans
COPD
Influenza
IPF
Oncology
Solid Tumors (Gastric, Pancreatic, Liver Glioblastoma, Lung, Breast) 
Autoimmune
IBD (includes Crohn’s and Ulcerative Colitis)
Lupus
Psoriasis
FSGS
RA
Diabetes
Acute
Cytokine release syndrome
Acute Coronary Syndrome
GVHD
Sepsis
Muscle Degeneration
FSHD
DMD
Neuro
Alzheimer’s
ALS
Multiple Sclerosis
Cellular Aging
Werner’s Syndrome 
Hearing Loss

We chose ARDS as our first-to-market indication

ARDS is an acute diffuse, inflammatory lung injury, leading to increased pulmonary vascular permeability, increased lung weight, and loss of aerated lung tissue. In ARDS, fluid leaks into lungs making it difficult to absorb oxygen and the patient cannot breathe

Learn more about ARDS

Highlights

GEn1E’s team, led by Dr. Ritu Lal, has decades of experience working on drug development and platform technologies

Key building blocks of GEn1E Platform

Database

Curated database includes GEn1E generated proprietary data for our drugs as well curated data for inflammatory and rare diseases

Mapper

Each inflammatory disease has its own unique signature as expressed with multiple biomarkers. The platform matches our drug’s unique signature with the inflammatory disease signature to select the best match of our drug for the disease

Machine Learning Engine

We utilize a continuous feedback loop across the entire process from discovery to clinical studies.
Neural Networks, Gradient Boosting Methods and Hidden Markov Models are used to accelerate drug development

Team has strong domain expertise in developing NextGenImmunomodulators

The founding CEO, Dr. Ritu Lal, has taken drugs from discovery through FDA approval 3 times. She has formed a world-class team, which includes stellar Advisors and many of the world’s top ARDS experts

Strong domain expertise in drug development and ML platform development 
Team includes world’s leading ARDS experts
Backed by stellar Investors, Advisors and Accelerators

Get in touch with us!

We are based in Palo Alto, CA, and have a laboratory in Mountain View, CA.

We look forward to joining forces with you to cure rare and inflammatory diseases, fast!

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.